This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, top-performing sectors, and what’s next for biotech investors.

This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.

Analyst Faisal Khurshid applauded Abivax's obefazimod, an oral drug developed to treat moderately to severely active ulcerative colitis, as a catalyst for strong gains ahead. "We view obefazimod (obe) ...

Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered to tell the biotech sector. Biotech stocks lagged the broader market in ...

The average one-year price target for Rossari Biotech (NSEI:ROSSARI) has been revised to ₹ 648.21 / share. This is a decrease of 21.79% from the prior estimate of ₹ 828.85 dated January 11, 2026. The ...

The biotech industry has delivered an upbeat performance so far in 2026 despite an uncertain macroeconomic backdrop. Strong fourth-quarter results, better visibility, new drug approvals and ...

Some artificial intelligence (AI)-focused companies have delivered exceptional returns over the past few years, but some ...